# Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

> **NCT03334617** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 528 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Danvatirsen
- **DRUG:** Ceralasertib
- **DRUG:** Vistusertib
- **DRUG:** Olaparib
- **DRUG:** Oleclumab
- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Cediranib

## Key facts

- **NCT ID:** NCT03334617
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-18
- **Primary completion:** 2024-09-13
- **Final completion:** 2026-09-11
- **Target enrollment:** 528 (ACTUAL)
- **Last updated:** 2025-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03334617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03334617, "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03334617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*